NCT03645928 2025-06-19
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
13 trialsNCT01676649 2021-02-18
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
Jewish General Hospital
Phase 2 Active not recruiting
NCT02617849 2021-02-18
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Jewish General Hospital
Phase 2 Unknown
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00404235 2018-10-16
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01174238 2018-06-08
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT00626405 2018-05-01
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00434252 2017-07-18
BEAM
Genentech, Inc.
Phase 2 Completed
NCT02023710 2017-05-09
Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00976573 2017-04-04
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01200342 2016-02-11
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01014351 2014-03-26
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00288041 2013-03-05
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed